Acute ischemic stroke is a leading cause of death and major disability worldwide.
Approximately 50% of ischemic strokes are caused by atherothrombotic occlusion of the …

Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known,
estimates about the two most widely used antiplatelet agents–aspirin and clopidogrel …

Oral antiplatelet drugs, including aspirin, clopidogrel and extendedrelease dipyridamole, are
widely prescribed for the secondary prevention of vascular events, including stroke. Despite …

Aspirin is a well-established medication in the treatment of atherothrombotic vascular
disease. However, despite aspirin treatment a substantial number of patients experience …

The aim of this review is to introduce the concept of personalized medicine in secondary
stroke prevention with antiplatelet medication. In the last years, many studies have been …

for which it is intended or failure of the agent to achieve the biochemical (pharmacokinetic
and/or pharmacodynamic) effect. Because of the complex pathophysiology of ischemic heart …

Stroke is one of the world's leading causes of disability and death. Antiplatelet agents are
administered to acute ischemic stroke patients as secondary prevention. Clopidogrel …

We review the role of aspirin and clopidogrel for prevention of ischemic stroke and explore
the concept of antiplatelet therapy resistance both from a laboratory and clinical perspective …

Background: The combination of clopidogrel and aspirin is recommended for the treatment
of patients with acute minor stroke or transient ischemic attack (TIA). However, with varied …

Variable platelet response to aspirin and clopidogrel is a well-established phenomenon in
patients with coronary artery disease. We sought to determine the predictors of an impaired …